Can-Fite BioPharma Ltd.

Can-fite Biopharma Ltd.

Biotechnology • Healthcare • Ramat Gan, Israel • CANF (ASE)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

972 3 924 1114 26 Ben Gurion Street, Israel

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction - Investing.com
Investing.com • Dec 26
Can-Fite BioPharma Shares Surged 50% In Pre-Market On Brazilian Patent Win - Stocktwits
Stocktwits • Dec 26
Brazil grants patent for a new way to tackle sexual dysfunction - Stock Titan
Stock Titan • Dec 26
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - GlobeNewswire
GlobeNewswire • Dec 23
Can-Fite BioPharma shares surged 50% in pre-market on Brazilian patent win - MSN
MSN • Dec 26

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Can-Fite BioPharma Ltd. had layoffs?
No layoff events have been recorded for Can-Fite BioPharma Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has approximately 5 employees.
What industry is Can-Fite BioPharma Ltd. in?
Can-Fite BioPharma Ltd. operates in the Biotechnology industry, within the Healthcare sector.
Is Can-Fite BioPharma Ltd. a publicly traded company?
Yes, Can-Fite BioPharma Ltd. is publicly traded under the ticker symbol CANF on the ASE. The company has a market capitalization of approximately $0.00 billion.
Where is Can-Fite BioPharma Ltd. headquartered?
Can-Fite BioPharma Ltd. is headquartered in Ramat Gan, Israel at 26 Ben Gurion Street, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.